Literature DB >> 26405565

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.

Anna Vilgelm1, Ann Richmond1.   

Abstract

We recently demonstrated that dual therapy combining AURKA and MDM2 antagonists is effective against melanoma in preclinical settings. Notably, besides inducing apoptosis, this regimen led to tumor senescence and stimulated the host's antitumor immune defenses. Treatments leveraging both cancer cell-intrinsic and extrinsic antitumor mechanisms can improve melanoma therapeutic outcomes.

Entities:  

Keywords:  Aurora kinase; apoptosis; melanoma; p53; senescence

Year:  2015        PMID： 26405565      PMCID： PMC4570092          DOI： 10.1080/2162402X.2015.1009299

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Reversal of human cellular senescence: roles of the p53 and p16 pathways.

Authors:  Christian M Beauséjour; Ana Krtolica; Francesco Galimi; Masashi Narita; Scott W Lowe; Paul Yaswen; Judith Campisi
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

3.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

4.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 5.  Senescence at a glance.

Authors:  Jeff S Pawlikowski; Peter D Adams; David M Nelson
Journal:  J Cell Sci       Date:  2013-08-22       Impact factor: 5.285

6.  A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.

Authors:  Clemens A Schmitt; Jordan S Fridman; Meng Yang; Soyoung Lee; Eugene Baranov; Robert M Hoffman; Scott W Lowe
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

7.  Polyploidy road to therapy-induced cellular senescence and escape.

Authors:  Qin Wang; Peter C Wu; David Z Dong; Iana Ivanova; Elizabeth Chu; Steven Zeliadt; Hubert Vesselle; Daniel Y Wu
Journal:  Int J Cancer       Date:  2012-11-16       Impact factor: 7.396

Review 8.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02

Review 9.  Four faces of cellular senescence.

Authors:  Francis Rodier; Judith Campisi
Journal:  J Cell Biol       Date:  2011-02-14       Impact factor: 10.539

10.  Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Authors:  Yan Liu; Oriana E Hawkins; Yingjun Su; Anna E Vilgelm; Tammy Sobolik; Yee-Mon Thu; Sara Kantrow; Ryan C Splittgerber; Sarah Short; Katayoun I Amiri; Jeffery A Ecsedy; Jeffery A Sosman; Mark C Kelley; Ann Richmond
Journal:  EMBO Mol Med       Date:  2012-11-25       Impact factor: 12.137
  10 in total
  5 in total

1.  Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Authors:  Anna E Vilgelm; C Andrew Johnson; Nripesh Prasad; Jinming Yang; Sheau-Chiann Chen; Gregory D Ayers; Jeff S Pawlikowski; Dayanidhi Raman; Jeffrey A Sosman; Mark Kelley; Jeffrey A Ecsedy; Yu Shyr; Shawn E Levy; Ann Richmond
Journal:  J Natl Cancer Inst       Date:  2015-12-30       Impact factor: 13.506

2.  MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Authors:  Anna E Vilgelm; Nabil Saleh; Rebecca Shattuck-Brandt; Kelsie Riemenschneider; Lauren Slesur; Sheau-Chiann Chen; C Andrew Johnson; Jinming Yang; Ashlyn Blevins; Chi Yan; Douglas B Johnson; Rami N Al-Rohil; Ensar Halilovic; Rondi M Kauffmann; Mark Kelley; Gregory D Ayers; Ann Richmond
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

3.  Antitumorigenic effect of damnacanthal on melanoma cell viability through p53 and NF-κB/caspase-3 signaling pathways.

Authors:  Xin Zhang; Ping Fang; Zigang Zhao; Xiangyu Ding; Fang Xie; Yilin Wang; Chengxin Li
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

4.  MDM2 Antagonists Counteract Drug-Induced DNA Damage.

Authors:  Anna E Vilgelm; Priscilla Cobb; Kiran Malikayil; David Flaherty; C Andrew Johnson; Dayanidhi Raman; Nabil Saleh; Brian Higgins; Brandon A Vara; Jeffrey N Johnston; Douglas B Johnson; Mark C Kelley; Sheau-Chiann Chen; Gregory D Ayers; Ann Richmond
Journal:  EBioMedicine       Date:  2017-09-19       Impact factor: 8.143

Review 5.  Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.

Authors:  Anna E Vilgelm; Ann Richmond
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.